Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients with Early Recurrent Prostate Cancer

Clinical Nuclear Medicine

Volumn 41, Issue 9, 2016, Pages e397-e402

  Rauscher, Isabel ^a   Maurer, Tobias ^a   Souvatzoglou, Michael ^a,b   Beer, Ambros J ^b   Vag, Tibor ^a   Wirtz, Martina ^c   Weirich, Gregor ^a   Wester, Hans Jürgen ^c   Gschwend, Jürgen E ^a   Schwaiger, Markus ^a   Schottelius, Margret ^c   Eiber, Matthias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

111In PSMA I T; biochemical recurrence; hybrid imaging; prostate cancer; PSMA ligand; SPECT CT

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EDETIC ACID; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; INDIUM; MEMBRANE ANTIGEN; N,N'-BIS(2-HYDROXY-5-(ETHYLENE-BETA-CARBOXY)BENZYL)ETHYLENEDIAMINE N,N'-DIACETIC ACID;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; EARLY CANCER; GLEASON SCORE; HUMAN; MALE; PET-CT SCANNER; PROSTATE CANCER; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TUMOR RECURRENCE;

AGED; ANTIGENS, SURFACE; EDETIC ACID; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY;

EID: 84973281859     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001273     Document Type: Article

References (34)

1. Siegel R Ma J Zou Z Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Freedland SJ Presti JC Jr Amling CL Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003; 61: 736-741.
3. Han M Partin AW Zahurak M Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523.
4. 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013; 64: 106-117.
5. Evangelista L Guttilla A Zattoni F Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013; 63: 1040-1048.
6. Eder M Eisenhut M Babich J PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013; 40: 819-823.
7. 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012; 2: 23.
8. 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int J Urol. 2014; 21: 1286-1288.
9. Afshar-Oromieh A Zechmann CM Malcher A Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41: 11-20.
10. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56: 668-674.
11. 68Ga-HBED-PSMA. J Clin Oncol. 2015; 68: 530-504.
12. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015; 56: 1169-1176.
13. Weineisen M Simecek J Schottelius M Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014; 4: 63.
14. Herrmann K Bluemel C Weineisen M Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015; 56: 855-861.
15. 177Lu PSMA small molecules in combination with Ga-68 PSMA PET/CT. Nuklearmediziner. 2015: 145-152.
16. Suardi N Gandaglia G Gallina A Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015; 67: 299-309.
17. Abdollah F Briganti A Montorsi F Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol. 2015; 67: 839-849.
18. Maurer T Weirich G Schottelius M Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015; 68: 530-534.
19. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35: 18-23.
20. Souvatzoglou M Eiber M Martinez-Moeller A PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013; 40 (suppl 1): S79-S88.
21. Khalil MM Tremoleda JL Bayomy TB Molecular SPECT imaging: an overview. Int J Mol Imaging. 2011; 2011: 796025.
22. Mojtahedi A Thamake S Tworowska I The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging. 2014; 15: 426-434.
23. 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol. 2011; 13: 583-593.
24. 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51: 875-882.
25. Hofman MS Kong G Neels OC High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012; 56: 40-47.
26. Reubi JC Schär JC Waser B Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27: 273-282.
27. Schottelius M Wirtz M Eiber M [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015; 5: 68.
28. Al-Nahhas A Win Z Szyszko T What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging. 2007; 34: 1897-1901.
29. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013; 54: 1369-1376.
30. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014; 55: 1791-1798.
31. Hinkle GH Burgers JK Neal CE Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998; 83: 739-747.
32. Raj GV Partin AW Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002; 94: 987-996.
33. Thomas CT Bradshaw PT Pollock BH Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003; 21: 1715-1721.
34. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013; 40: 971-972.